The radioisotope contributes significantly to the activity of radioimmunotherapy

Clinical Cancer Research

Volumn 10, Issue 23, 2004, Pages 7792-7798

  Davis, Thomas A ^a,h   Kaminski, Mark S ^b   Leonard, John P ^c   Hsu, Frank J ^e   Wilkinson, Mary ^f   Zelenetz, Andrew ^d   Wahl, Richard L ^b   Kroll, Stewart ^g   Coleman, Morton ^c   Goris, Michael ^a   Levy, Ronald ^a   Knox, Susan J ^a  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e YALE UNIVERSITY   (United States)

^f INOVA FAIRFAX HOSPITAL   (United States)

^g GLAXOSMITHKLINE   (United States)

^h EPN 7025 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTHRAQUINONE; ANTIBIOTIC AGENT; FLUDARABINE; GYRASE INHIBITOR; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131;

ADULT; AGED; ARTICLE; ASTHENIA; BLOOD TOXICITY; CHILL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOSIMETRY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FEVER; FOLLOW UP; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELODYSPLASIA; MYELODYSPLASTIC SYNDROME; NAUSEA; NONHODGKIN LYMPHOMA; OUTCOMES RESEARCH; PAIN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RASH; SEROCONVERSION; SERUM SICKNESS; THYROTROPIN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IODINE RADIOISOTOPES; LYMPHOMA, B-CELL; LYMPHOMA, LOW-GRADE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIOIMMUNOTHERAPY; REMISSION INDUCTION;

EID: 9744233595     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0756     Document Type: Article

References (23)

1. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33.
2. Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980;125:1678-85.
3. Buchsbaum DJ, Wahl RL, Normolle DP, Kaminski MS. Therapy with unlabeled and 131-I-labeled pan B cell monoclonal antibodies in nude mice bearing Raji Burkitt lymphoma xenografts. Cancer Res 1992;52:6476-81.
4. Maloney D, Smith B, Appelbaum F. The antitumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma cell lines [abstract]. Blood 1996;88:637a.
5. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998;91:1644-52.
6. Weiner LM. Monoclonal antibody therapy of cancer. Semin Oncol 1999;26:43-51.
7. Press OW. Prospects for the management of non-Hodgkin's lymphomas with monoclonal antibodies and immunoconjugates. Cancer J Sci Am 1998;4(Suppl 2):S19-26.
8. Press OW. Radiolabeled antibody therapy of B-cell lymphomas. Semin Oncol 1999;26:58-65.
9. Nourigat C, Badger CC, Bernstein ID. Treatment of lymphoma with radiolabeled antibody: elimination of tumor cells lacking target antigen. J Natl Cancer Inst (Bethesda) 1990;82:47-50.
10. Zelenetz A, Leonard J, Bennett J, Kaminski M. Long-term follow-up of patients with low-grade and transformed low-grade NHL treated with Bexxar therapy [abstract]. Proc Am Soc Clin Oncol 2002;21:1128.
11. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2000;18:1316-23.
12. Kaminski MS, Zelenetz AD, Press OW, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918-28.
13. Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3262-9.
14. Wahl RL, Kroll S, Zasadny KR. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. J Nucl Med 1998;39:14S-20S.
15. Kaminski MS, Zasadny KR, Francis IR, et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993;329:459-65.
16. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 1996;14:1974-81.
17. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-95.
18. Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000;18:3135-43.
19. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer (Phila) 1982;49:2112-35.
20. Salacinski PR, McLean C, Sykes JE, Clement-Jones W, Lowry PJ. Iodination of proteins, glycoproteins, and peptides using a solid-phase oxidizing agent, 1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenyl glycoluril (Iodogen). Anal Biochem 1981;117:136-46.
21. Loevinger R, Budinger T, Watson E. MIRD primer for absorbed dose calculations. Reston, VA: The Society of Nuclear Medicine, Inc.; 1988.
22. Witzig TE, Gordon LI, Cabanillas F, et al. A. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453-63.
23. Bennett J, Zelenetz A, Press O, et al. Incidence of myelodysplastic syndromes and acute myeloid leukemia in patients with low-grade non-Hodgkin's lymphoma treated with Bexxar [abstract 1416]. Blood 2001;98(Suppl):335a.